Yahoo Finance

Tessellate BIO, an Emerging Precision Oncology Company, Announces the Appointment of World-Leading Scientists to its Scientific Advisory Board

AMSTERDAM and LONDON, Nov. 15, 2023 (GLOBE NEWSWIRE) -- Tessellate BIO, a preclinical stage biotechnology company with a focus on novel Synthetic Lethality approaches, today announces the appointment ...
Yahoo Finance

Tessellate Bio Appoints Katie Chapman as Chief Scientific Officer

NAARDEN, the Netherlands and STEVENAGE, United Kingdom, Oct. 01, 2025 (GLOBE NEWSWIRE) -- Tessellate Bio, a precision oncology company with a focus on developing novel synthetic lethality approaches, ...
Pharmabiz

Tessellate BIO, Omico & CMRI collaborate to accelerate discovery of synthetic lethal precision therapies to address ‘ALT’ cancers

Tessellate BIO, a preclinical stage biotechnology company with a focus on novel Synthetic Lethality approaches, announces a collaboration with CMRI, a leading Australian paediatric medical research ...
manilatimes

Tessellate BIO Announces Appointment of Lara Boyd as Chief Business Officer

AMSTERDAM and STEVENAGE, United Kingdom, Nov. 04, 2024 (GLOBE NEWSWIRE) -- Tessellate BIO, a preclinical stage biotechnology company with a focus on novel Synthetic Lethality approaches, today ...
Pharmabiz

Boehringer Ingelheim & Tessellate Bio partner to develop first-in-class precision treatments for people with hard-to-treat cancers

Boehringer Ingelheim, is a biopharmaceutical company, and Tessellate Bio, a precision oncology company with a focus on developing novel synthetic lethality approaches, have entered into a research ...
PMLiVE

Boehringer Ingelheim and Tessellate Bio enter oncology partnership worth over €500m

Boehringer Ingelheim and Tessellate Bio have entered into a partnership worth over €500m to develop oral precision medicines for hard-to-treat cancers. The research collaboration and global licence ...
PharmiWeb

Tessellate BIO, Omico and CMRI announce a multi-year collaboration to accelerate discovery of synthetic lethal precision therapies to address ‘ALT’ cancers

Amsterdam, the Netherlands and Sydney, Australia 30 September 2024 - Tessellate BIO, a preclinical stage biotechnology company with a focus on novel Synthetic Lethality approaches, announces a ...